Title: Study the influence of arthritis on breast cancer associated bone metastasis INTRODUCTION: Metastasis is regulated not only by intrinsic genetic changes in malignant cells, but also by the microenvironment. Several studies have demonstrated that sites of chronic inflammation are often associated with the establishment and growth of various malignancies (1) . A common inflammatory condition in humans is autoimmune arthritis (AA) that causes inflammation and deformity of the joints. Other systemic effects associated with arthritis include increased cellular infiltration and inflammation of the lungs (2) . Several studies have also reported statistically significant risk ratios between AA and various malignancies including breast, lung, hematopoietic, nonmelanotic skin, kidney, and colon (3, 4) (5,6). Despite this knowledge available for a decade, it has never been questioned if a site of chronic inflammation linked to AA creates a milieu that attracts tumor cells to home and grow in the inflamed bones and lungs which are frequent sites of breast cancer metastasis (7) . The preference of breast cancer cells to grow in the bone and lung is underscored by the fact that 65-75% of patients with advanced disease develop metastases in these organs. Yet, it is not known why and how breast cancer cells prefer to colonize these organs. There are no methods to predict the risk of breast cancer-associated metastasis and current treatments have notable limitations.
Original Hypothesis: Chronic inflammatory milieu and osteoclastic bone resorption caused by autoimmune arthritis may influence the recruitment, retention, and proliferation of tumor cells in the bone and promote metastasis. Although we set out to only study bone metastasis, we discovered that AA has a significant effect on lung metastasis as well and therefore we have included data on bone and lung metastasis.
BODY:
AIM 1: To determine the incidence and frequency of bone metastasis in a spontaneous model of autoimmune arthritis injected with syngeneic metastatic or non metastatic breast cancer cells (4T1 or TUBO cell lines respectively) in the mammary fat pad. The data from this aim has been submitted for publication to Nature Medicine. A pdf of the manuscript is attached (appendix 1).
AIM 2:
To determine if bone metastasis develops in mouse models of spontaneous breast cancer.
The PyV MT mice that develop spontaneous cancer are injected with 2mgs/ml Type II collagen (CII) to induce arthritis at two time points: when the mice are 9 weeks in pre-metastatic condition and when the mice are 18 weeks with primary tumors large enough and metastasis is expected to occur. Emulsified CII in CFA was injected intradermally (i.d) in the skin of the tail at approximately 1.5 cm distal to the base of the tail. Approximately 60% of the mice injected with CII developed inflammation in the joints. Between 21 and 23 weeks, mice were sacrificed and arthritic limbs were represented by high cellular infiltration in the bones (Figure 1 ). This inflammation resulted in an increase in the primary tumor burden in the arthritic PyV MT mice versus the control PyV MT mice regardless of whether arthritis was induced at 9 or 18 weeks of age ( Figure 2 ). This was further substantiated by the increased presence of proliferating cells within the tumor of the arthritic PyV MT mice compared to nonarthritic PyV MT mice ( Figure 3 ). This was determined by proliferating cell nuclear antigen (PCNA) staining of the tumor sections. When bone marrow of these mice was examined, we observed a significant increase in circulating epithelial tumor cells in the arthritic PyV MT mice versus non-arthritic PyV MT mice. Although bone lesions were not observed in the PyV MT mice, the increased pancytokerain+ cells in the marrow is a clear indication of increased tumor cell recruitment to the bone. This may be because the mice cannot be aged beyond 23 weeks, as the primary tumor burden reaches 10% of the body weight and due to IACUC regulations; the mice have to sacrificed at that time. In the future, we propose to surgically remove the primary tumor and allow the animals age to follow bone lesions. With regard to lung metastasis, we observed a significant increase in the incidence of metastasis in arthritic (27% in 9-week CII mice and 36% in 18-week CII mice) versus the non-arthritic PyV MT mice (0%) ( Figure 5 ). Most importantly, the arthritic PyV MT mice have lower survival (21 weeks) compared to the non-arthritic PyV MT (26 weeks) mice.
Mechanistically, several factors were discovered to be critical for the increased primary tumor and metastasis. First, there were increased pro-inflammatory factors such as COX-2, PGE2, VegF, and CD31 in the arthritic bones of PyV MT mice as well as in the primary tumor along with higher cellular infiltration in the bones and lungs. Second, the level of circulating IL-17 was increased in the arthritic PyV MT mice. Third, there was a significant decrease in NK cells and significant increase myeloid suppressor (CD11b 
Concluding Remarks and Future Direction for Aims 1 and 2:
A schematic representation of a proposed vicious cycle of osteolytic metastasis is illustrated in Figure 6 . We have been able to test this phenomenon directly using the SKG and the PyV MT models. These studies warrant further investigation into understanding the key mechanism that drives increased breast cancer-associated metastasis in arthritic mice. One suggested mechanism (that was previously reported is schematically illustrated in Figure 7 ) which can be tested for the first time in our models.
Chemokine receptor CXCR4
Chemokines such as CXCL12 recognize these receptors. 
Malignant

AIM 3:
The efficacy of anti-IL-17 antibody treatment in combination with COX-2 inhibitor was more efficacious than either treatment alone in the prevention of bone and lung metastasis in the arthritic (SKG) mice bearing the metastatic breast tumor. The treatment schedule and dose was described in the proposal. The data also suggest that these two agents were not able to completely prevent metastasis from occurring. Other factors have to be evaluated. The primary tumor was removed before treatment was started. Similar results were observed with the EP2 receptor antagonist as celecoxib (data not shown). 
AIM 4:
Analysis of archival cases of breast cancer patients from 1996 to 2007, revealed a trend towards a positive correlation between metastasis and AA, however, due to diverse treatment regimen, statistical significance was not reached. Mayo Clinic Arizona Cancer Registry was used to sort analytical female breast malignancies from 1996-2007. Total of three thousand seven hundred and eighty patient records were evaluated. Out of these there were approximately 567 had metastatic disease in various sites including multiple sites. 63 patients had bone metastasis and only 13 were alive beyond one year. Fifty patients with bone metastasis died within one year of diagnosis. Almost all patients suffered from some form of AA. Since many of the non-metastatic breast cancer patients also had AA, the statistical analysis did not reveal a clear correlation. The data is however extremely enticing and many more patients need to be evaluated in the future.
KEY RESEARCH ACCOMPLISHMENTS:
• Significantly increased bone and lung metastasis is observed in mice with AA • Future funding is being seeked to continue this important study from NIH and DOD
REPORTABLE OUTCOMES:
• SKG mice data: Manuscript submitted to Nature Medicine • AA affects both lung and bone metastasis associated with breast cancer
CONCLUSION:
We have been able to directly test using the SKG and the PyV MT models that a vicious circle of osteolytic metastasis occurs in which both the severity of arthritis and bone destruction is enhanced by metastatic tumor cells and that the arthritic miluei attracts and retains metastatic tumor cells in the site of inflammation. In addition the arthritic milieu increases the primary tumor burden. The two diseases feed of each other. The results warrant further investigation into understanding the key mechanism that drives increased breast cancer-associated metastasis in arthritic mice. One suggested mechanism is the CXCR4 and CXCL-12 interaction which can be tested for the first time in our models. The combination of celecoxib and anti-IL-17 shows impressive results but is not enough to prevent metastasis from occurring. Other factors that we identified especially IL-6, and VegF may play critical role. Whether a combination therapy can be developed that target multiple cytokines for preventing metastasis remains to be investigated. More human data has to be analyzed from multiple cancer centers to determine a statistical correlation. 
Breast Cancer Associated Metastasis is
ABSTRACT
Chronic inflammation is known to play a role in cancer initiation, promotion, and metastasis, however, the mechanism by which inflammation promotes metastasis is still unclear. We evaluated if chronic inflammation induced by autoimmune arthritis may contribute to increased breast cancer-associated metastasis. We report a three-fold increase in lung metastasis and a significant increase in the incidence of bone metastasis (9), similar to the effects of anticytokine therapy in human arthritis (10) . These clinical and immunopathological characteristics of arthritis in these mice make the strain a suitable model for testing our hypothesis. The SKG mice were induced to develop mammary gland tumors by injecting syngeneic breast cancer cell lines, 4T1 (metastatic) or TUBO (non-metastatic) in the mammary fat pad. We found a three-fold increase in lung metastasis in the arthritic versus the non-arthritic mice and a significant increase in the incidence of osteolytic bone lesions in the arthritic mice.
We identified the key pro-inflammatory factors that contribute to the increased incidence of breast cancer-associated secondary metastasis and to the severity of the bone disease.
The finding provides a novel role of autoimmune arthritis and inflammation in promoting breast cancer associated metastasis to the site of inflammation.
RESULTS
Metastatic breast cancer cells contribute to the severity of arthritis in the SKG mice
SKG mice treated with one dose of zymosan A extract developed full-blown arthritis within 30-45 days with macroscopic evidence of joint swelling in the fingers and in the fore and hind limbs (as illustrated in Fig 1. c-f ). Thirty-days post zymosan A injection, mice were challenged with 1x10 6 syngeneic breast cancer cells (4T1 being metastatic or TUBO being non-metastatic) in the mammary fat pad. Age-matched SKG mice without zymosan injection were used as the pro-arthritic model, and Balb/c mice were used as the non-arthritic controls. Compared to the Balb/c control (Fig 1. a) and the pro-arthritic SKG (Fig 1. b) mice, the joint swelling was 5-fold and 2-fold higher in the SKG + zymosan + 4T1 (Fig 1. e and f) and SKG + zymosan + TUBO (Fig 1. c and d ) mice respectively. More interestingly, the joints of the SKG + zymosan + 4T1 mice showed a 2-fold increase in swelling than the SKG + zymosan + TUBO mice ( It must be noted that 4T1 or TUBO-challenged SKG mice without zymosan did not show gross macroscopic evidence of joint swelling (data not shown), however, when hematoxylin & eosin (H&E) stained sections from the joints of 4T1-challenged SKG mice were examined, we observed severe inflammation as evidenced by the high degree of cellular infiltration into the bone joints (Fig 1. k) . That however was not the case in the joints of TUBO-challenged SKG mice (Fig 1. i) providing further evidence that factors from the metastatic 4T1 breast cancer cells contribute to the severity of inflammation in the pro-arthritic SKG mice. Highest severity of synovial hyperplasia and erosion of articular cartilage and bone in the phalangeal joints of the hind limb resulting in severe cellular infiltration and inflammation was found in joints of the SKG + zymosan + 4T1 mice (Fig1. l). As was expected, the SKG + zymosan + TUBO mice also showed synovial hyperplasia and erosion of articular cartilage and bone in the hind limb joints (Fig 1. j) but the severity of destruction was much less than evidenced with 4T1 challenge (Fig 1. l) . The severity of inflammation in the TUBO challenged SKG + zymosan mice (Fig 1. j) with the non-metastatic TUBO cells (Fig 1. n) indicating that the tumor -type did not matter and that the innate immune responses elicited by zymosan injection regulate the primary tumor growth but not the secondary metastasis as discussed in the next section.
Three-fold increase in breast cancer-associated lung metastasis in pro-arthritic and arthritic mice augmented by severe inflammation in the lungs
More than three fold increase in lung metastasis was observed in the SKG mice challenged with the metastatic 4T1 breast cancer cells as compared to the non-arthritic Balb/c mice (Fig 2. g -i and were no metastatic lesions in lungs of control Balb/c, SKG, and SKG-zymosan mice without tumor challenge (Fig 2. a -c, and j) . Representative lungs from each experimental group are shown (Fig 2. a -i ).
To investigate a mechanism of the increased lung metastasis in the pro-arthritic and arthritic mice, we first examined the lung histology. It became apparently clear that all lungs that developed metastasis were packed with interstitial inflammatory cellular infiltrate characterized by prominent neutrophilic and granulocytic cells and activated macrophages (Fig 2. m-v and Table 1 ). We graded the severity of lung infiltration and arbitrarily assigned levels of infiltration as 'no', 'low', 'medium', and 'high'. Table 1 shows a correlation between the level of lung infiltration and severity of lung metastasis in all mice. Along with the cellular infiltrates, epithelial metastatic lesions were identified in the lungs as indicated by the solid yellow arrowheads (Fig 2. p, r and t) . The infiltration was most prominent in the lungs of the SKG mice (+/-zymosan) bearing the 4T1 breast tumors (Fig 2.r and (Fig 2.u) , SKG + zymosan (Fig 2. v, Balb/c + TUBO (Fig 2. m) , SKG + TUBO (Fig 2. n, Balb/c + zymosan + TUBO (Fig 2. o) , and Balb/c + zymosan + 4T1 (Fig 2. s) mice all show normal lung architecture which correlate with zero lung lesions ( Table 1 ). The one mouse in Balb/c + 4T1 group that developed lung lesions also showed low-level cellular infiltrates (Fig 2. q and Table 1a ). Thus, a high degree of correlation exists between cellular infiltrates in the lungs and lung metastasis (Table 1) (Fig 2. w) . With the TUBO-challenged mice, the analysis was not as clear since TUBO cells are normally non-metastatic (Fig 2. w) .
Increased expression of pancytokeratin positive epithelial cells in the arthritic bones coupled with increased expression of CD31 and COX-2.
Since cellular infiltration in the lungs greatly facilitated the recruitment of breast cancer cells to the site (Fig 2.) , we examined if high infiltration/inflammation in the bones of the arthritic mice had a similar effect. We have already shown that there is increased cellular infiltration in the bones of arthritic mice challenged with the 4T1 tumors (Fig 1. k and l) , and that the bone infiltration correlated statistically with the severity of lung metastasis (Fig 2. j, k, l and w). We examined the levels of pro-inflammatory factors in the bone that Increased expression of pancytokeratin-positive areas was only evident in the bones of the arthritic mice challenged with the 4T1 tumors (Fig 3. n and p) . Bones from all other experimental groups were negative (Fig 3. m, o, q, and r) . Brown staining represents CD31, COX-2, and pancytokeratin positivity. Bones from n=10 mice were examined with similar staining patterns.
Increased 4T1 bone lesions in the arthritic versus non-arthritic mice
The bone from n = 4 -5 mice were analyzed by Faxitron imaging. Representative images are shown in Fig 3. s -x. Osteolytic and/or sclerotic bone lesions were determined in ~50% (2/4) of SKG mice and 33% (2/5) of the SKG + zymosan mice challenged with the 4T1 metastatic tumor cells (Fig 3. v and w) . These bones show distinct radiolucencies in the distal femoral diametaphysis indicating apparent osteolytic bone lesion (as indicated by the arrows). In contrast, none of the Balb/c mice challenged with 4T1 tumors developed bone lesions (Fig 3. t) nor did SKG mice challenged with TUBO cells (Fig 3. s, u, and x). The results indicate that bone lesions only occur in the pro-arthritic bones but not in non-arthritic bones (Fig 3. y) .
M-CSF, IL-6, IL-17, TNF-α and VegF are the underlying factors for increased metastasis=associated with 4T1 tumors in the arthritic mice.
To determine the possible mechanism that drives the 4T1 cells to become more metastatic in the arthritic model, we evaluated the circulating levels of pro-inflammatory cytokines and chemokines in the sera of the arthritic versus non-arthritic mice. A custom mouse cytokine array was designed to test the sera for the presence of 10 cytokines known to be associated with AA, inflammation, and metastasis. These included macrophage colony stimulating factor (M-CSF), tumor necrosis factor-alpha (TNF-α),
Interferon-gamma (IFN-γ), VegF, Interleukin-17 (IL-17), matrix metalloproteinase-2 (MMP-2), Interleukin-6 (IL-6), Insulin-like growth factor-II (IGF-II), Interleukin-1beta
(IL-1β), and Interleukin-4 (IL-4) (Fig 4. g) and Balb/c mice that were not challenged with any tumor showed similar cytokine levels as TUBO-challenged mice (data not shown).
DISCUSSION
The main goal of this study was to determine if inflammation in the bone and other organs caused by AA supports secondary metastasis associated with breast cancer. We establish that the chronic inflammation in the bone and lung caused by AA and the subsequent increase in circulating levels of proinflammatory cytokines may be the underlying mechanism contributing to the increased metastasis (schematically represented in Fig 5. i) .
Results from the preclinical studies clearly indicate that breast cancer associated metastasis to the lung and bone is increased in the arthritis mice versus the non-arthritic mice (Fig 2 and 3) . In addition, the metastatic breast cancer cells accentuate the severity of bone inflammation in the arthritic mice (Fig 1) . This is partly explained by the fact that breast tumor cells produce factors that directly or indirectly induce the formation of osteoclasts. In turn, bone resorption by osteoclasts releases growth factors from the bone matrix that stimulate primary tumor growth, and bone destruction. This reciprocal interaction between breast-cancer cells and the bone microenvironment results in a vicious circle that increases both bone destruction and the tumor burden (17) . The fact that the primary tumor burden is not increased in the SKG mice injected with zymosan (Fig 1m and n) can be explained by the fact that zymosan, a crude yeast cell wall extract activates the arthritogenic T cells through stimulating the innate immune response (11), which may help keep the primary tumor in check but does not reduce the incidence of metastasis.
We report that chronic inflammatory milieu and osteoclastic bone resorption caused by autoimmune arthritis influences the recruitment, retention, and proliferation of tumor cells not only to the bone (Fig 3) but also to the lungs (Fig 2) . In fact a three fold increase in lung metastasis was observed in the arthritic mice challenged with the 4T1 breast cancer cells regardless of whether the SKG mice received zymosan A (Fig 2 and Table   I ). The lungs of arthritic mice with the 4T1 metastatic lesions express exceptionally high levels of interstitial inflammatory cellular infiltrates characterized by prominent neutrophils, mast cells, activated macrophages, and possibly eosinophils (Fig 2.r and t) .
A statistical correlation was also observed between the severity of inflammation in the bone and the incidence of metastatic lung lesions (Fig 2. w and Table 1 ). Although it has been established that pro-inflammatory leukocytes alone can facilitate tumor cell extravasation and promote metastasis (18) , this is the first study that establishes a correlation between the pro-inflammatory cell recruitment in the lungs during arthritis and the homing of the circulating cancer cells in the highly inflamed lungs (Figure 2 and Table 1 ).
Inflammation is a critical component of tumor progression and metastasis as well as arthritis (12,13,14, and 15) . Many processes that occur during arthritis also occur during tumorigenesis. There is uncontrollable growth and inflammation in both; there is increased vascularity in both; and there are common cytokines and growth factors that are regulated in both. Many cancers including breast cancer may arise from sites of infection, chronic irritation, and inflammation. The tumor microenvironment, which is largely orchestrated by inflammatory cells, is critical in the neoplastic process, fostering proliferation, survival and migration (16) . It is indeed interesting that post-menopausal women who are usually prone to developing some form of AA including osteoarthritis or inflammatory polyarthritis are also most likely to get breast cancer. Thus, it is not unlikely that the two diseases co-exist in these women. Our study begins to evaluate whether these two disease states molecularly interact and feed of each other.
Two of the pro-inflammatory factors that may contribute to the metastatic dissemination of breast cancer cells are COX-2 and VegF, both of which are activated during arthritis and breast cancer (25) . We observe overexpression of COX-2 and VegF in the 4T1 tumors in the SKG mice with or without zymosan as compared to the tumors in the nonarthritic Balb/c mice (data not shown). Higher expression of COX-2 and VegF in tumors of the arthritic mice may indicate resistance to programmed cell death as well as increased cell migration, proliferation, and angiogenesis (19, 20, 21, and 22) . High expression of VegF in AA is usually in response to high TNF-α (Fig 4) , increasing endothelial permeability and swelling and also stimulating angiogenesis in the joints. The arthritic bone milieu is therefore comprised of inflammatory cells, cytokines, chemokines, cyclooxygenases (COX), lipooxygenase (LOX), and various eicosanoids, that may attract and foster tumor cells to the inflamed site (25) . Our data goes a step further to suggest that the increased CD31 and COX-2 expression in the bones of arthritic SKG mice is promoted by metastatic breast tumor cells (Fig 3. a-f and g-l) . Faxitron imaging of the bones suggested apparent osteolytic bone lesions only in the arthritic SKG mice challenged with 4T1 cells (Fig 4. v and w) which was corroborated by the presence of pancytokeratin (epithelial cell) positive patches (Fig 3. n and p) .
As in human AA, cytokines play an essential role in the development of arthritis in the SKG mice (9) . Several cytokines have been implicated in the mechanism of synovial cell activation and joint destruction in AA (27) . In our study, serum analysis of cytokine proteins revealed higher expression of M-CSF, IL-17, IL-6, TNF-α, and VegF in the arthritic mice only when challenged with 4T1 metastatic breast cancer cells (Fig 4) .
Elevated serum M-CSF predicts reduced survival in metastatic breast cancer patients. The M-CSF produced by breast cancer cells and surrounding stromal cells increases osteoclast formation and maturation and enhances the expression of stromal RANK ligand, both of which increase osteolytic bone degradation (33) . IL-17 has been identified as a crucial cytokine for osteoclastic bone resorption in AA patients. IL-17 acts on osteoblasts by stimulating COX-2-dependent prostaglandin E 2 (PGE 2 ), and osteoclast differentiation factor which differentiates osteoclast progenitors into mature osteoclasts, causing bone resorption. PGE 2 interacts with its eicosanoid receptors to induce the damage (26) . IL-6 is an autocrine and paracrine growth factor for several cancers, including breast cancer (29) and stimulates cancer cell growth and contributes to recurrence and metastasis in breast cancer (30) . VegF is known to play a critical role in vasculogenesis, angiogenesis, and metastasis. Upregulation of these cytokines may therefore account for the enhanced breast cancer associated secondary metastasis as well as accentuating the severity of arthritis in the SKG mice. Thus, blocking these proinflammatory cytokines may hold promise in reducing the severity of both diseases.
In conclusion, our data for the first time, implicate that chronic inflammation in the bone and lungs caused by AA creates a milieu that attract metastatic breast tumor cells to home and proliferate in those inflamed sites. These studies may have important clinical implications, especially in the prevention of secondary metastasis, in designing combination drug regimens, and as a diagnostic risk-assessment tool.
MATERIALS AND METHODS
Mice
SKG mice have been established from the closed breeding colony of Balb/c mice (8) .
Two sets of SKG breeding pairs were purchased from CLEA International Japan and were breeded in our animal facility. All protocols were approved by the Mayo Clinic
Internal Animal Care Review Committee.
Induction of Arthritis
The SKG mice fail to develop detectable arthritis in a microbially clean environment, despite their thymic production of arthritogenic autoimmune T cells that persist in the periphery. However, zymosan A, a crude yeast cell wall extract, can provoke arthritis in SKG mice (11) . Two month old mice were given a single intraperitoneal (ip) injection of 
Induction of Tumor
One million 4T1 and TUBO cells were injected directly into the mammary fat pad of female arthritic SKG and non-arthritic Balb/c mice. The tumors were visible in the mammary fat pad in 5-7 days. The tumors were allowed to grow for 4 weeks and animals sacrificed thereafter.
Measurement of cytokines using Custom Mouse Cytokine/Chemokine Antibody
Array kit
The RayBio® Custom Mouse Cytokines Antibody Array kit was purchased from RayBiotech (Norcross, GA) and used according to the manufacturer's instructions.
Briefly, after blocking, membranes were incubated for 1.45 h with the experimental serum. The membranes were washed and incubated with biotin-conjugated antibodies for
1.45 h. The membranes were washed again and incubated with streptavidin-conjugated horseradish peroxidase (HRP) for 2 h, washed, and developed using an enhanced chemiluminescent substrate for HRP. Chemiluminescence was detected using a EpiChemi3® Darkroom imaging system and LabWorks® densitometry software (both from UVP Bioimaging, Upland, CA). Data was corrected for background signal and normalized to positive controls using RayBio® Analysis Tool software.
Histologic and immunohistochemical staining
Lungs and a part of the tumor were formalin fixed in 10% neutral-buffered formalin (pH 
Statistical analysis:
Student's t-test was used for comparing the level of significance between the experimental groups. Correlation Coefficient was determined using the JMP statistical program. Table 1 Group 
